Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy (NCT07122466)
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy in Patients With Advanced Pancreatic Cancer: a Prospective, Observational Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
Who can join: Review the eligibility criteria below.
Location: Zuckerberg Cancer Center — New Hyde Park, New York
Age range: 18 Years
🧪 Interventions in This Study
- Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Zuckerberg Cancer Center — New Hyde Park, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Pancreatic Cancer
- Proglumide and Chemotherapy for Metastatic Pancreatic Cancer — Washington D.C., District of Columbia
- Saltikva for Metastatic Pancreatic Cancer — Montreal, Quebec
- Redefining FOLFIORINOX in Older Pancreatic Cancer Patients — Philadelphia, Pennsylvania
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. — Baltimore, Maryland
- Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer — Dallas, Texas
Explore by condition: All Metastatic Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.